Alcyone Therapeutics
David Donabedian is on the Board of Directors at Alcyone Therapeutics. David is also the Co-founder, CEO and Director at Axial Biotherapeutics & Venture Partner, Longwood Fund.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Alcyone Therapeutics
Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-generation CNS delivery technology platform. Alcyone Therapeutics’ lead programs target the treatment of Rett syndrome and spinal muscular atrophy with respiratory distress type 1 (SMARD1).